- Home
- CTSO vs STTK Comparison
CTSO vs STTK Comparison
Compare CTSO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- STTK
- Stock Information
- Founded
- CTSO 1997
- STTK 2016
- Country
- CTSO United States
- STTK United States
- Employees
- CTSO N/A
- STTK N/A
- Industry
- CTSO Medical/Dental Instruments
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- CTSO Health Care
- STTK Health Care
- Exchange
- CTSO Nasdaq
- STTK Nasdaq
- Market Cap
- CTSO 51.6M
- STTK 56.8M
- IPO Year
- CTSO N/A
- STTK 2020
- Fundamental
- Price
- CTSO $1.08
- STTK $1.20
- Analyst Decision
- CTSO Strong Buy
- STTK Hold
- Analyst Count
- CTSO 3
- STTK 3
- Target Price
- CTSO $4.67
- STTK $2.00
- AVG Volume (30 Days)
- CTSO 159.7K
- STTK 224.1K
- Earning Date
- CTSO 05-08-2025
- STTK 05-01-2025
- Dividend Yield
- CTSO N/A
- STTK N/A
- EPS Growth
- CTSO N/A
- STTK N/A
- EPS
- CTSO N/A
- STTK N/A
- Revenue
- CTSO $37,739,531.00
- STTK $6,435,000.00
- Revenue This Year
- CTSO $9.20
- STTK $313.04
- Revenue Next Year
- CTSO $11.64
- STTK N/A
- P/E Ratio
- CTSO N/A
- STTK N/A
- Revenue Growth
- CTSO 1.80
- STTK 382.75
- 52 Week Low
- CTSO $0.70
- STTK $0.94
- 52 Week High
- CTSO $1.61
- STTK $11.76
- Technical
- Relative Strength Index (RSI)
- CTSO 45.16
- STTK 50.41
- Support Level
- CTSO $0.99
- STTK $1.18
- Resistance Level
- CTSO $1.15
- STTK $1.39
- Average True Range (ATR)
- CTSO 0.08
- STTK 0.20
- MACD
- CTSO -0.02
- STTK -0.02
- Stochastic Oscillator
- CTSO 10.53
- STTK 15.79
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.